ASCITES study
Recruiting
- Conditions
- In advanced stage ovarian cancer patients 20-30% of the patients do not respond to primary (chemotherapy) treatment. 20-30% van de patiënten met gevorderd ovariumcarcinoom heeft geen goede respons op de 1e keus chemotherapie die wordt gegeven.
- Registration Number
- NL-OMON20712
- Lead Sponsor
- Radboudumc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
-Histologically confirmed ovarian, tubal or extra-ovarian peritoneal cancer
Exclusion Criteria
-Previous chemotherapy
-Previous or concurrent malignant disease except basal cell carcinoma
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Development and validation of a precision medicine approach based on the analysis of drug sensitivity markers in ascites of ovarian cancer patients.
- Secondary Outcome Measures
Name Time Method 1.To compare clinical response on chemotherapy with the histopathological response seen in the tumor after neoadjuvant chemotherapy. To develop a new (histopathologic) parameter of response that is applicable in daily practice. <br /><br><br /><br>2. To study the immunological response in ascites of EOC patients before and after chemotherapy. To come to a better understanding of the role of the immune system in the development of ovarian cancer.<br>